Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference
May 17 2022 - 8:00AM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on the discovery and development of targeted cell
therapies for patients with autoimmune diseases, today announced
that Steven Nichtberger, M.D., President and Chief Executive
Officer, will participate in a fireside chat at the H.C. Wainwright
Global Investment Conference on Tuesday, May 24, 2022 at 11:00 a.m.
ET in Miami, FL.
A live webcast of the presentation will be available on the
News and Events section of the Company’s website at
www.cabalettabio.com. Replays of the presentation will be available
on the website for 30 days.
About Cabaletta BioCabaletta Bio (Nasdaq: CABA)
is a clinical-stage biotechnology company focused on the discovery
and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™
platform, in combination with Cabaletta Bio’s proprietary
technology, has advanced a growing pipeline that currently includes
potential treatments for patients with mucosal pemphigus vulgaris,
MuSK-associated myasthenia gravis, PLA2R-associated membranous
nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with
FVIII alloantibodies. Cabaletta Bio’s headquarters are located in
Philadelphia, PA. For more information,
visit www.cabalettabio.com and follow us on LinkedIn.
Contacts:
Anup MardaChief Financial Officerinvestors@cabalettabio.com
Sarah McCabeStern Investor Relations,
Inc.sarah.mccabe@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Sep 2023 to Sep 2024